Advinus joins CGH to develop therapies for Visceral Leishmaniasis
The aim of the partnership is to identify and develop compounds that are safe and effective against VL parasites. The collaboration underlines the relative experience and expertise of
The US Food and Drug Administration (FDA) has approved PharmaEssentia’s Besremi (ropeginterferon alfa-2b-njft) to treat adults with essential thrombocythaemia (ET).